低剂量IL-2治疗新诊断1型糖尿病儿童:一项I/II期随机双盲安慰剂对照剂量探索研究
DF-IL2-Child研究为多中心、双盲、安慰剂对照的I/II期剂量探索试验,纳入24例新诊断1型糖尿病儿童,随机分配至安慰剂或IL-2 0.125、0.250、0.500 MIU/m²组。结果显示低剂量IL-2呈剂量依赖性增加调节性T细胞(Treg)比例,无严重不良事件,但血糖控制无显著变化;Treg高反应者1年时诱导的C肽产生维持更好。
要点
- 低剂量IL-2在所有剂量组均呈剂量依赖性增加Treg比例,且与安慰剂有显著差异。
- 7例Treg高反应者均来自0.250和0.500 MIU/m²剂量组,其1年时诱导的C肽产生维持优于低反应者。
- 各剂量组血糖控制与安慰剂相比无显著变化,常见非严重不良事件为注射部位反应。
核心结论
- 所有剂量的安全性、对Treg的剂量依赖性效应以及Treg反应的变异性,要求未来开发中使用最高剂量。
- Treg高反应者胰岛素产生维持更好,支持Treg调节1型糖尿病自身免疫的潜力,并值得继续研究低剂量IL-2用于其治疗和预防。
研究设计与样本
- DF-IL2-Child为在法国四所大学医院中心开展的多中心、双盲、安慰剂对照、剂量探索I/II期临床试验。
- 纳入24例7-14岁、诊断3个月内的1型糖尿病儿童,按1:1:1:1随机分配至安慰剂或IL-2 0.125、0.250、0.500 MIU/m²组,分布为7/5/6/6例。
- 给药方案为每日一次连续5天,之后每两周一次,持续1年。
- 主要结局为第5天Treg占CD4+ T细胞百分比的变化,预设Treg较基线增加≥60%定义为Treg高反应者。
主要发现
- 无严重不良事件;非严重不良事件为暂时性、轻至中度,治疗患者 vs 安慰剂最常见的非严重不良事件为注射部位反应(37.9% vs 3.4%),其他非严重不良事件水平相同(23.3% vs 19.2%)。
- 低剂量IL-2诱导Treg平均比例呈剂量依赖性增加,从最低剂量的23.9%(95%CI -11.8, 59.6)至最高剂量的77.2%(44.7, 109.8),所有剂量组与安慰剂相比均有显著差异。
- 个体Treg对IL-2的反应可变且随时间波动;7例Treg高反应者均来自0.250和0.500 MIU m⁻² day⁻¹剂量组。
- 基线时Treg高反应者CD4+细胞中Treg比例低于Treg低反应者,血清可溶性IL-2受体α(sIL-2RA)和血管内皮生长因子受体2(VEGFR2)水平预测5天疗程后的Treg反应。
- 与安慰剂相比,任何剂量组的血糖控制均无显著变化;但7例Treg高反应者1年时诱导的C肽产生维持优于低反应者。
临床怎么用
- 原文结论指出,未来开发中应使用最高剂量。
- 作者认为,Treg高反应者胰岛素产生维持更好支持Treg调节1型糖尿病自身免疫的潜力,并值得继续研究低剂量IL-2用于其治疗和预防。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: Low-dose IL-2 (ld-IL2) selectively activates and expands regulatory T cells (Tregs) and thus has the potential to skew the regulatory/effector T (Treg/Teff) cell balance towards improved regulation. We investigated which low doses of IL-2 would more effectively and safely activate Tregs during a 1 year treatment in children with recently diagnosed type 1 diabetes. METHODS: Dose Finding Study of IL-2 at Ultra-low Dose in Children With Recently Diagnosed Type 1 Diabetes (DF-IL2-Child) was a multicentre, double-blinded, placebo-controlled, dose-finding Phase I/II clinical trial conducted in four centres at university hospitals in France: 24 children (7-14 years old) with type 1 diabetes diagnosed within the previous 3 months were randomly assigned 1:1:1:1 to treatment by a centralised randomisation system, leading to a 7/5/6/6 patient distribution of placebo or IL-2 at doses of 0.125, 0.250 or 0.500 million international units (MIU)/m2, given daily for a 5 day course and then fortnightly for 1 year. A study number was attributed to patients by an investigator unaware of the randomisation list and all participants as well as investigators and staff involved in the study conduct and analyses were blinded to treatments. The primary outcome was change in Tregs, expressed as a percentage of CD4+ T cells at day 5. It pre-specified that a ≥60% increase in Tregs from baseline would identify Treg high responders. RESULTS: There were no serious adverse events. Non-serious adverse events (NSAEs) were transient and mild to moderate. In treated patients vs placebo, the commonest NSAE was injection site reaction (37.9% vs 3.4%), whereas other NSAEs were at the same level (23.3% vs 19.2%). ld-IL2 induced a dose-dependent increase in the mean proportion of Tregs, from 23.9% (95% CI -11.8, 59.6) at the lowest to 77.2% (44.7, 109.8) at the highest dose, which was significantly different from placebo for all dose groups. However, the individual Treg responses to IL-2 were variable and fluctuated over time. Seven patients, all among those treated with the 0.250 and 0.500 MIU m-2 day-1 doses, were Treg high responders. At baseline, they had lower Treg proportions in CD4+ cells than Treg low responders, and serum soluble IL-2 receptor α (sIL-2RA) and vascular endothelial growth factor receptor 2 (VEGFR2) levels predicted the Treg response after the 5 day course. There was no significant change in glycaemic control in any of the dose groups compared with placebo. However, there was an improved maintenance of induced C-peptide production at 1 year in the seven Treg high responders as compared with low responders. CONCLUSIONS/INTERPRETATION: The safety profile at all doses, the dose-dependent effects on Tregs and the observed variability of the Treg response to ld-IL2 in children with newly diagnosed type 1 diabetes call for use of the highest dose in future developments. The better preservation of insulin production in Treg high responders supports the potential of Tregs in regulating autoimmunity in type 1 diabetes, and warrants pursuing the investigation of ld-IL2 for its treatment and prevention. TRIAL REGISTRATION: ClinicalTrials.gov NCT01862120. FUNDING: Assistance Publique-Hôpitaux de Paris, Investissements d'Avenir programme (ANR-11-IDEX-0004-02, LabEx Transimmunom and ANR-16-RHUS-0001, RHU iMAP) and European Research Council Advanced Grant (FP7-IDEAS-ERC-322856, TRiPoD).
引用
- Rosenzwajg M, Salet R, Lorenzon R, et al. Low-dose IL-2 in children with recently diagnosed type 1 diabetes: a Phase I/II randomised, double-blind, placebo-controlled, dose-finding study. Diabetologia. 2020. PMID: 32607749. doi:10.1007/s00125-020-05200-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。